TABLE 1.
Demographics and PD characteristics
Variable | GBA PD | LRRK2 PD | sPD |
---|---|---|---|
BL Visit, N = 80 | BL Visit, N = 158 | Year 2 Visit, N = 361 | |
Age, mean (SD) | 62.7 (9.9) | 63.8 (9.2) | 63.8 (9.7) |
Sex, male, n (%) | 43 (53.8)a | 76 (48.1)a | 238 (65.9) |
Education, <13 y, n (%) | 12 (15.0) | 35 (22.2) | 62 (17.2) |
Ethnicity, Hispanic/Latino, n (%) | 1 (1.3) | 39 (24.7)a,b | 8 (2.2) |
Race, n (%) | |||
White | 76 (95.0) | 139 (88.5) | 332 (92.0) |
Missing | 0 | 1 | 0 |
Family history of PD, n (%) | |||
First degree | 18 (22.8) | 72 (47.1)a, b | 47 (13.1) |
Second degree | 11 (13.9) | 25 (16.3) | 42 (11.7) |
None | 50 (63.3) | 56 (36.6) | 271 (75.3) |
Missing | 1 | 5 | 1 |
Genetic mutation, n (%) | |||
G2019S | 0 (0.0) | 140 (88.6) | — |
R1441C | 0 (0.0) | 1 (0.6) | — |
R1441G | 0 (0.0) | 16 (10.1) | — |
N1437H | 0 (0.0) | 1 (0.6) | — |
N370S (c. 1226A>G) | 71 (88.8) | 0 (0.0) | — |
L483P or L444P (c.1448T > C) | 6 (7.5) | 0 (0.0) | — |
84GG (c.84_85insG) | 3 (3.8) | 0 (0.0) | — |
Disease duration, y | |||
Mean (SD) | 3.1 (2.0) | 2.9 (1.9) | 2.6 (0.6) |
Median (minimum, maximum) | 3.0 (0.0, 7.1)c | 2.4 (0.1, 6.9) | 2.4 (2.0, 4.9)d |
Age at PD symptom onset, mean (SD) | 58.4 (10.7) | 58.8 (9.9) | 59.7 (9.9) |
P < 0.05 versus sPD.
P < 0.05 versus GBA PD.
Two GBA PD subjects had disease durations <7 years at screening, but exceeded 7 years by the time of their baseline assessment.
Seven sPD subjects had disease durations <2 years at screening, but exceeded 4 years at year 2 as a result of scheduling delays; 10 sPD subjects had disease durations >2 years at screening, but a waiver was granted allowing them to enroll in the study.
Report generated on data submitted as of July 1, 2019. P values were found using t tests (age and age at PD symptom onset), Wilcoxon rank-sum tests (disease duration), and χ2 tests (all categorical variables).
PD, Parkinson’s disease; GBA, glucosylceramidase beta; LRRK2, leucine rich kinase 2; sPD, sporadic PD; BL, baseline; SD, standard deviation.